WO2008043461A3 - Inhibition der pde2a - Google Patents

Inhibition der pde2a Download PDF

Info

Publication number
WO2008043461A3
WO2008043461A3 PCT/EP2007/008561 EP2007008561W WO2008043461A3 WO 2008043461 A3 WO2008043461 A3 WO 2008043461A3 EP 2007008561 W EP2007008561 W EP 2007008561W WO 2008043461 A3 WO2008043461 A3 WO 2008043461A3
Authority
WO
WIPO (PCT)
Prior art keywords
prophylaxis
diseases
pde2a
inhibition
atherosclerosis
Prior art date
Application number
PCT/EP2007/008561
Other languages
English (en)
French (fr)
Other versions
WO2008043461A2 (de
Inventor
Peter Ellinghaus
Andreas Wilmen
Martin Hendrix
Adrian Tersteegen
Original Assignee
Bayer Healthcare Ag
Peter Ellinghaus
Andreas Wilmen
Martin Hendrix
Adrian Tersteegen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Peter Ellinghaus, Andreas Wilmen, Martin Hendrix, Adrian Tersteegen filed Critical Bayer Healthcare Ag
Priority to EP07818641A priority Critical patent/EP2124955A2/de
Priority to US12/444,708 priority patent/US20100035882A1/en
Priority to CA002666355A priority patent/CA2666355A1/en
Priority to JP2009531740A priority patent/JP2010506561A/ja
Publication of WO2008043461A2 publication Critical patent/WO2008043461A2/de
Publication of WO2008043461A3 publication Critical patent/WO2008043461A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)

Abstract

Die Erfindung betrifft die Verwendung von PDE2A-Inhibitoren zur Herstellung eines Arzneimittels zur Behandlung und/oder Prophylaxe von koronaren Herzkrankheiten, insbesondere stabiler und instabiler Angina pectoris, akutem Myokardinfarkt, Myokardinfarktprophylaxe, Herzinsuffizienz, sowie Bluthochdruck und den Folgen der Atherosklerose, sowie Gefäßerkrankungen, Erkrankungen der Niere, insbesondere Nierenversagen, entzündlichen Erkrankungen, Erektionsstörungen und Verhinderung des plötzlichen Herztodes.
PCT/EP2007/008561 2006-10-14 2007-10-02 Inhibition der pde2a WO2008043461A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP07818641A EP2124955A2 (de) 2006-10-14 2007-10-02 Inhibition der pde2a
US12/444,708 US20100035882A1 (en) 2006-10-14 2007-10-02 Inhibition of pde2a
CA002666355A CA2666355A1 (en) 2006-10-14 2007-10-02 Inhibition of pde2a
JP2009531740A JP2010506561A (ja) 2006-10-14 2007-10-02 Ｐｄｅ２ａの阻害

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006048693.5 2006-10-14
DE102006048693A DE102006048693A1 (de) 2006-10-14 2006-10-14 Inhibition der PDE2A

Publications (2)

Publication Number Publication Date
WO2008043461A2 WO2008043461A2 (de) 2008-04-17
WO2008043461A3 true WO2008043461A3 (de) 2008-08-28

Family

ID=39184962

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/008561 WO2008043461A2 (de) 2006-10-14 2007-10-02 Inhibition der pde2a

Country Status (6)

Country Link
US (1) US20100035882A1 (de)
EP (1) EP2124955A2 (de)
JP (1) JP2010506561A (de)
CA (1) CA2666355A1 (de)
DE (1) DE102006048693A1 (de)
WO (1) WO2008043461A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
MY173949A (en) 2012-04-25 2020-02-28 Takeda Pharmaceuticals Co Nitrogenated heterocyclic compound
EP2873669A4 (de) 2012-07-13 2015-11-25 Takeda Pharmaceutical Heterocyclische verbindung
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2014142255A1 (ja) 2013-03-14 2014-09-18 武田薬品工業株式会社 複素環化合物
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
US10053468B2 (en) 2013-07-03 2018-08-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9815796B2 (en) 2013-12-23 2017-11-14 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as PDE2 inhibitors
JP2017114764A (ja) * 2014-04-25 2017-06-29 武田薬品工業株式会社 片頭痛治療剤
EP3156405A1 (de) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclische etherderivate von pyrazolo[1,5-a]pyrimidin-3-carboxamid
EP3713572A1 (de) 2017-11-23 2020-09-30 Oslo University Hospital HF Behandlung von tachykardie

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4278673A (en) * 1977-03-25 1981-07-14 Allen & Hanburys Limited Pharmacologically active compounds
WO2004044234A1 (en) * 2002-11-13 2004-05-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a)
US20060168668A1 (en) * 2003-04-04 2006-07-27 Memory Pharmaceuticals Corporation Phosphodiesterase 2a and methods of use
WO2007100618A2 (en) * 2006-02-23 2007-09-07 Atto Bioscience Novel cell-based phosphodiesterase assays

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0113343D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel Heterocycles 2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4278673A (en) * 1977-03-25 1981-07-14 Allen & Hanburys Limited Pharmacologically active compounds
WO2004044234A1 (en) * 2002-11-13 2004-05-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a)
US20060168668A1 (en) * 2003-04-04 2006-07-27 Memory Pharmaceuticals Corporation Phosphodiesterase 2a and methods of use
WO2007100618A2 (en) * 2006-02-23 2007-09-07 Atto Bioscience Novel cell-based phosphodiesterase assays

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CASTRO L R V ET AL: "Cyclic guanosine monophosphate compartimentation in rat cardiac myocytes", CIRCULATION, vol. 113, 1 May 2006 (2006-05-01), pages 2221 - 2228, XP002477670 *
IFFLAND A ET AL: "Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system", BIOCHEMISTRY, vol. 44, 2005, pages 8312 - 8325, XP002477671 *

Also Published As

Publication number Publication date
JP2010506561A (ja) 2010-03-04
EP2124955A2 (de) 2009-12-02
WO2008043461A2 (de) 2008-04-17
DE102006048693A1 (de) 2008-04-17
US20100035882A1 (en) 2010-02-11
CA2666355A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
WO2008043461A3 (de) Inhibition der pde2a
WO2010042163A3 (en) Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
PL3026044T3 (pl) Inhibitory prolilo-hydroksylazy i sposoby ich użycia
EA201070339A1 (ru) Активаторы растворимой гуанилатциклазы
WO2009067600A3 (en) Biaryl pde4 inhibitors for treating inflammation
EP2213668A3 (de) Imidazole als Aldosterone Synthase Inhibitoren
WO2006056889A3 (en) Method and composition for enhancing anti-angiogenic therapy
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
WO2007117982A3 (en) Organic compounds
UY28958A1 (es) Nuevos derivados de piridazin-3(2h)-ona
CY1112215T1 (el) Πιμοβενδανη που θα χρησιμοποιηθει για τη μειωση του μεγεθους της καρδιας σε θηλαστικα που υποφερουν απο καρδιακη ανεπαρκεια
EA201171361A1 (ru) Ингибиторы внешнего медуллярного калиевого канала почек
WO2007041368A3 (en) Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
EP2674417A3 (de) Biaryl-PDE4-Inhibitoren zur Behandlung von Entzündungen
WO2006034402A3 (en) Compounds for inflammation and immune-related uses
WO2004020410A3 (en) Dihydropyridinone derivatives as hne inhibitors
WO2008061720A3 (en) Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders
NO20070827L (no) Farmasoytiske formuleringer inneholdende en blodplateaggregregeringsinnhibitor og et fibrat.
WO2007019153A3 (en) Methods for treating hypertension
WO2010030891A3 (en) Aryl guanidine f1f0-atpase inhibitors and related methods
IL186374A (en) Combined use of prostaglandin compound and ppi for the manufacture of pharmacological compounds for the treatment of gastrointestinal disorders and pharmaceutical compounds containing them
WO2007014033A3 (en) Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure
WO2009074969A3 (en) Spingosine-1-phosphate, analogues and antagonists for use as medicaments
WO2011149288A3 (ko) 복수의 타이로신 카이네이즈에 대한 저해 활성을 가지는 항염증 화합물 및 이를 포함하는 약학적 조성물

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2007818641

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12444708

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2666355

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009531740

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07818641

Country of ref document: EP

Kind code of ref document: A2